Literature DB >> 34406864

TMPRSS2 Activates Hemagglutinin-Esterase Glycoprotein of Influenza C Virus.

Ko Sato1,2,3, Hideki Hayashi4, Yoshitaka Shimotai5, Mutsuo Yamaya6, Seiji Hongo5, Kazuyoshi Kawakami2,3, Yoko Matsuzaki5, Hidekazu Nishimura1.   

Abstract

Influenza C virus (ICV) has only one kind of spike protein, the hemagglutinin-esterase (HE) glycoprotein. HE functions similarly to hemagglutinin (HA) and neuraminidase of the influenza A and B viruses (IAV and IBV, respectively). It has a monobasic site, which is cleaved by some host enzymes. The cleavage is essential to activating the virus, but the enzyme or enzymes in the respiratory tract have not been identified. This study investigated whether the host serine proteases, transmembrane protease serine S1 member 2 (TMPRSS2) and human airway trypsin-like protease (HAT), which reportedly cleave HA of IAV/IBV, are involved in HE cleavage. We established TMPRSS2- and HAT-expressing MDCK cells (MDCK-TMPRSS2 and MDCK-HAT). ICV showed multicycle replication with HE cleavage without trypsin in MDCK-TMPRSS2 cells as well as IAV did. The HE cleavage and multicycle replication did not appear in MDCK-HAT cells infected with ICV without trypsin, while HA cleavage and multistep growth of IAV appeared in the cells. Amino acid sequences of the HE cleavage site in 352 ICV strains were completely preserved. Camostat and nafamostat suppressed the growth of ICV and IAV in human nasal surface epithelial (HNE) cells. Therefore, this study revealed that, at least, TMPRSS2 is involved in HE cleavage and suggested that nafamostat could be a candidate for therapeutic drugs for ICV infection. IMPORTANCE Influenza C virus (ICV) is a pathogen that causes acute respiratory illness, mostly in children, but there are no anti-ICV drugs. ICV has only one kind of spike protein, the hemagglutinin-esterase (HE) glycoprotein on the virion surface, which possesses receptor-binding, receptor-destroying, and membrane fusion activities. The HE cleavage is essential for the virus to be activated, but the enzyme or enzymes in the respiratory tract have not been identified. This study revealed that transmembrane protease serine S1 member 2 (TMPRSS2), and not human airway trypsin-like protease (HAT), is involved in HE cleavage. This is a novel study on the host enzymes involved in HE cleavage, and the result suggests that the host enzymes, such as TMPRSS2, may be a target for therapeutic drugs of ICV infection.

Entities:  

Keywords:  HAT; HE; TMPRSS2; influenza C virus; serine protease

Mesh:

Substances:

Year:  2021        PMID: 34406864      PMCID: PMC8513465          DOI: 10.1128/JVI.01296-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

Review 1.  Understanding influenza virus pathogenicity.

Authors:  W Garten; H D Klenk
Journal:  Trends Microbiol       Date:  1999-03       Impact factor: 17.079

2.  Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein.

Authors:  H Kido; Y Yokogoshi; K Sakai; M Tashiro; Y Kishino; A Fukutomi; N Katunuma
Journal:  J Biol Chem       Date:  1992-07-05       Impact factor: 5.157

3.  Cloning and characterization of the cDNA for human airway trypsin-like protease.

Authors:  K Yamaoka; K Masuda; H Ogawa; K Takagi; N Umemoto; S Yasuoka
Journal:  J Biol Chem       Date:  1998-05-08       Impact factor: 5.157

4.  Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay.

Authors:  Mizuki Yamamoto; Shutoku Matsuyama; Xiao Li; Makoto Takeda; Yasushi Kawaguchi; Jun-Ichiro Inoue; Zene Matsuda
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

5.  Genetic Lineage and Reassortment of Influenza C Viruses Circulating between 1947 and 2014.

Authors:  Yoko Matsuzaki; Kanetsu Sugawara; Yuki Furuse; Yoshitaka Shimotai; Seiji Hongo; Hitoshi Oshitani; Katsumi Mizuta; Hidekazu Nishimura
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

6.  Clinical features of influenza C virus infection in children.

Authors:  Yoko Matsuzaki; Noriko Katsushima; Yukio Nagai; Makoto Shoji; Tsutomu Itagaki; Michiyo Sakamoto; Setsuko Kitaoka; Katsumi Mizuta; Hidekazu Nishimura
Journal:  J Infect Dis       Date:  2006-03-31       Impact factor: 5.226

7.  Proteolytic cleavage of influenza virus hemagglutinins: primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of Avian influenza viruses.

Authors:  F X Bosch; W Garten; H D Klenk; R Rott
Journal:  Virology       Date:  1981-09       Impact factor: 3.616

Review 8.  Host range restriction and pathogenicity in the context of influenza pandemic.

Authors:  Gabriele Neumann; Yoshihiro Kawaoka
Journal:  Emerg Infect Dis       Date:  2006-06       Impact factor: 6.883

9.  Analyses of Evolutionary Characteristics of the Hemagglutinin-Esterase Gene of Influenza C Virus during a Period of 68 Years Reveals Evolutionary Patterns Different from Influenza A and B Viruses.

Authors:  Yuki Furuse; Yoko Matsuzaki; Hidekazu Nishimura; Hitoshi Oshitani
Journal:  Viruses       Date:  2016-11-26       Impact factor: 5.048

10.  The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells.

Authors:  Mutsuo Yamaya; Yoshitaka Shimotai; Yukimasa Hatachi; Nadine Lusamba Kalonji; Yukiko Tando; Yasuo Kitajima; Kaori Matsuo; Hiroshi Kubo; Ryoichi Nagatomi; Seiji Hongo; Morio Homma; Hidekazu Nishimura
Journal:  Pulm Pharmacol Ther       Date:  2015-07-10       Impact factor: 3.410

View more
  1 in total

Review 1.  Host Non-Coding RNA Regulates Influenza A Virus Replication.

Authors:  Yuejiao Liao; Shouqing Guo; Geng Liu; Zhenyu Qiu; Jiamin Wang; Di Yang; Xiaojing Tian; Ziling Qiao; Zhongren Ma; Zhenbin Liu
Journal:  Viruses       Date:  2021-12-29       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.